6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A critical analysis of the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest concerns.
SUSTAIN-7 subgroup data: semaglutide beat dulaglutide on A1C and weight in nearly every subgroup, with largest gains in higher baseline BMI and A1C patients.
Deep dive into SUSTAIN-7 follow-up and extension data comparing semaglutide vs dulaglutide in type 2 diabetes, examining durability of A1C and weight effects, long-term safety signals, and what the original 40-week trial could not show.
A deep dive into the SUSTAIN-7 trial comparing semaglutide vs dulaglutide in type 2 diabetes, covering primary and secondary endpoint effect sizes, confidence intervals, time-course data, and response distributions.
Pratley, Aroda, Lingvay et al (Lancet Diabetes Endocrinol 2018;6(4):275-286) is SUSTAIN-7: semaglutide beat dulaglutide on A1C and weight at 40 weeks.
SUSTAIN-7 found semaglutide beat dulaglutide on A1C and weight loss at every dose over 40 weeks, reshaping GLP-1 prescribing and ADA guidance.